Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Pharmaceuticals, Inc.

http://www.regeneron.com

Latest From Regeneron Pharmaceuticals, Inc.

US Buy Of Lilly’s COVID-19 Therapy Now Turns On FDA's Manufacturing Quality Assessment

Under pressure to authorize use of Lilly’s bamlanivimab, the FDA must first weigh efficacy signals and GMP plant remediation progress.

Coronavirus COVID-19 Manufacturing

Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations

The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.

Coronavirus COVID-19 Pricing Debate

Lilly's US Bamlanivimab Contract Raises Difficult Allocation Considerations

The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.

Coronavirus COVID-19 Pricing Debate

Coronavirus Update: Lilly’s Antibody Plus Remdesivir Trial Abandoned

Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.

Companies Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Regeneron Genetics Center LLC (RGC)
UsernamePublicRestriction

Register